Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Oncology Report

• Publication date

  2006-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/OR.16.6.1301PMID 17089053
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging

  2006cited by this paper
• Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

  2006cited by this paper
• Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon

  2005cited by this paper
• Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.

  2005cited by this paper
• Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

  2005cited by this paper
• Identification of Overexpression and Amplification of ABCF2 in Clear Cell Ovarian Adenocarcinomas by cDNA Microarray Analyses

  2005cited by this paper
• Paclitaxel–platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial

  2004cited by this paper
• Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.

  2004cited by this paper
• UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer

  2004cited by this paper
• Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5

  2003cited by this paper
• Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients

  2003cited by this paper
• Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.

  2003cited by this paper
• Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma.

  2003cited by this paper
• Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5

  2003cited by this paper
• [Clinical characteristics of clear cell carcinoma of the ovary].

  2002cited by this paper
• Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

  2002cited by this paper
• Sensitivity to Anticancer Agents and Resistance Mechanisms in Clear Cell Carcinoma of the Ovary

  2002cited by this paper
• Clinical characteristics of clear cell carcinoma of the ovary

  2000cited by this paper
• Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary.

  2000cited by this paper
• A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma.

  1999cited by this paper
• Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer.

  1998cited by this paper
• Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum‐based chemotherapy

  1996cited by this paper
• Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease.

  1996cited by this paper
• Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.

  1996cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Synergistic Enhancement of Cisplatin Cytotoxicity by SN‐38, an Active Metabolite of CPT‐11, for Cisplatin‐resistant HeLa Cells

  1994cited by this paper
• Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages.

  1993cited by this paper
• Effects of CPT‐11 in combination with other anti‐cancer agents in culture

  1992cited by this paper
• Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.

  1991cited by this paper
• [International Histologic Classification of Tumors].

  1982cited by this paper
• MESONEPHROMA OVARII

  1948cited by this paper

• From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer

  2024cites this paper
• Clear Cell Carcinoma of the Ovary with Isolated Contiguous Hepatopulmonary Metastasis-A Case Report on a Surgically Challenging, Rare Presentation

  2024cites this paper
• Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer

  2023cites this paper
• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.

  2021cites this paper
• The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace.

  2020cites this paper
• Clinical management of epithelial ovarian cancer

  2018cites this paper
• Treatment of Rare Epithelial Ovarian Tumors.

  2018cites this paper
• Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.

  2016cites this paper
• Clear-cell carcinoma of the ovary.

  2016cites this paper
• Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma

  2015cites this paper
• Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives

  2015cites this paper
• PROGRESS IN THE TREATMENT OF OVARIAN CANCER. LESSONS FROM HOMOLOGOUS. RECOMBINATION DEFICIENCY

  2015cites this paper
• Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers

  2014cites this paper
• Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients

  2013cites this paper
• Specialized Pathology Review in Patients With Ovarian Cancer: Results From a Prospective Study

  2013cites this paper
• UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study.

  2013cites this paper
• Long‐term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first‐line chemotherapy

  2012influential citation
• Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents

  2012cites this paper
• Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma.

  2012cites this paper
• The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary

  2011cites this paper
• Ovarian Clear Cell Carcinoma

  2011cites this paper
• Clear Cell Cancers of Uterus

  2011cites this paper
• Clear Cell Carcinoma of the Ovary

  2011cites this paper
• Optimal primary surgical treatment for advanced epithelial ovarian cancer.

  2011cites this paper
• Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010.

  2011cites this paper
• Limits of 18F-Fluorodeoxyglucose Positron Emission Tomography in Recurrence Diagnosis of Borderline Ovarian Tumor

  2010cites this paper
• Chapter 8 – Chemotherapy for Ovarian Cancer

  2010cites this paper
• Relationship Between ABCF2 Expression and Response to Chemotherapy or Prognosis in Clear Cell Adenocarcinoma of the Ovary

  2010cites this paper
• Les tumeurs rares de l’ovaire : stratégies thérapeutiques en 2010, Observatoire francophone des tumeurs rares de l’ovaire et émergence des centres de références

  2010cites this paper
• Clear Cell Carcinoma of the Ovary: Prognosis Using Cytoreductive Surgery

  2010cites this paper
• [Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France].

  2010cites this paper
• Randomized Phase II Trial of Paclitaxel Plus Carboplatin Therapy Versus Irinotecan Plus Cisplatin Therapy as First-Line Chemotherapy for Clear Cell Adenocarcinoma of the Ovary: A JGOG Study

  2009cites this paper
• Current status of gynecologic cancer in Japan.

  2009cites this paper
• Clinical Significance of UDP-Glucuronosyltransferase 1A1*6 for Toxicities of Combination Chemotherapy with Irinotecan and Cisplatin in Gynecologic Cancers

  2009cites this paper
• Differential Expression of Hypoxia-Inducible Protein 2 Among Different Histological Types of Epithelial Ovarian Cancer and in Clear Cell Adenocarcinomas

  2009cites this paper
• Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives.

  2009cites this paper
• Les tumeurs malignes gynécologiques rares

  2008cites this paper
• Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma

  2008cites this paper
• Survival analysis of ovarian clear cell carcinoma confined to the ovary with or without comprehensive surgical staging.

  2008influential citation
• Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study

  2007cites this paper
• Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary.

  2007cites this paper